Description
Bone Marrow Microenvironment-Induced Resistance to Immunotherapeutic Agents in Multiple Myeloma
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: Bone Marrow Microenvironment-Induced Resistance to Immunotherapeutic Agents in Multiple Myeloma
€3.03
